Cellebrite DI's (CLBT) "Sell (D+)" Rating Reaffirmed at Weiss Ratings

Key Points

• Cellebrite DI (CLBT) has had its stock rating reaffirmed as "sell (D+)" by Weiss Ratings, indicating a bearish outlook from analysts.
• Despite the negative rating from Weiss, four other analysts have rated Cellebrite DI as a "buy," showing a divergence in analyst sentiment regarding the stock's prospects.
• The stock's average target price has shifted, with estimates ranging from $18.00 to $24.00 following various analysts' ratings adjustments.

Cellebrite DI (NASDAQ:CLBT - Get Free Report)'s stock had its "sell (d+)" rating reiterated by equities research analysts at Weiss Ratings in a report released on Friday,Weiss Ratings reports.

CLBT has been the topic of several other research reports. Needham & Company LLC decreased their price target on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating on the stock in a research report on Thursday, August 14th. Wall Street Zen raised shares of Cellebrite DI from a "hold" rating to a "buy" rating in a research report on Friday, September 26th. Lake Street Capital dropped their price objective on shares of Cellebrite DI from $24.00 to $22.00 and set a "buy" rating for the company in a research report on Friday, August 15th. Finally, JPMorgan Chase & Co. increased their target price on Cellebrite DI from $20.00 to $23.00 and gave the company an "overweight" rating in a research note on Wednesday, September 24th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $21.75.

Cellebrite DI Stock Performance

Cellebrite DI stock traded up $0.24 during midday trading on Friday, reaching $18.66. 699,421 shares of the company were exchanged, compared to its average volume of 1,207,544. The company has a market capitalization of $4.47 billion, a price-to-earnings ratio of 54.18, a P/E/G ratio of 3.35 and a beta of 1.29. The firm's 50-day simple moving average is $17.62 and its 200-day simple moving average is $16.94. Cellebrite DI has a 1 year low of $13.10 and a 1 year high of $26.30.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its earnings results on Thursday, August 14th. The company reported $0.12 EPS for the quarter, beating analysts' consensus estimates of $0.11 by $0.01. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The business had revenue of $113.28 million for the quarter, compared to the consensus estimate of $112.33 million. During the same quarter last year, the firm posted $0.10 EPS. The business's revenue for the quarter was up 18.4% compared to the same quarter last year. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, analysts forecast that Cellebrite DI will post 0.3 EPS for the current fiscal year.

Institutional Investors Weigh In On Cellebrite DI

A number of hedge funds have recently made changes to their positions in CLBT. Financial Management Professionals Inc. purchased a new position in Cellebrite DI during the 3rd quarter valued at about $28,000. CWM LLC raised its stake in Cellebrite DI by 85.7% during the 3rd quarter. CWM LLC now owns 1,560 shares of the company's stock valued at $29,000 after buying an additional 720 shares during the last quarter. Signaturefd LLC grew its position in shares of Cellebrite DI by 68.3% during the 2nd quarter. Signaturefd LLC now owns 2,019 shares of the company's stock valued at $32,000 after acquiring an additional 819 shares during the period. Assetmark Inc. purchased a new stake in Cellebrite DI in the 1st quarter worth $33,000. Finally, PNC Financial Services Group Inc. boosted its holdings in shares of Cellebrite DI by 1,998.0% during the 2nd quarter. PNC Financial Services Group Inc. now owns 2,098 shares of the company's stock valued at $34,000 after purchasing an additional 1,998 shares during the last quarter. 45.88% of the stock is currently owned by institutional investors.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.